STAT's video report examines the recent arrival of oral GLP-1 medications, marking a shift from injectable weight loss treatments. It highlights Novo Nordisk's release of an oral Wegovy and the anticipated approval of Eli Lilly's orforglipron. The discussion covers the scientific hurdles in developing effective pills and analyzes whether this new format will address ongoing challenges regarding drug pricing and patient accessibility.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.